Tekmira

July 21, 2015July 21, 2015

Tekmira to Change Name to Arbutus Biopharma, an HBV-Focused Company

News

Tekmira Pharmaceuticals Corporation has just revealed corporate plans to change its name to “Arbutus Biopharma Corporation”, shifting its focus to provide therapeutic solutions for chronic hepatitis B. This change will take ... Read more

March 23, 2015March 23, 2015

Three New Executive Members Join Tekmira to Address Hepatitis B

Hepatitis B, News

Biopharmaceutical company Tekmira Pharmaceuticals Corporation has appointed three new executive members to support their mission of finding a cure for chronic hepatitis B virus infection (HBV). The new senior vice president of ... Read more

March 13, 2015March 13, 2015

Tekmira Completes Merger With OnCore for Hepatitis Research

Hepatitis B, News

Tekmira Pharmaceuticals Corporation recently announced the completion of its merger with OnCore Biopharma, Inc. The merger enables the creation of a top-industry therapeutic solutions firm committed to developing a cure to address chronic hepatitis B virus infection (HBV) ... Read more

February 4, 2015February 5, 2015

Tekmira Begins Phase I Clinical Trial Of TKM-HBV For Hepatitis B

News

Tekmira Pharmaceuticals Corporation, a leading company in the development of RNA interference (RNAi) therapeutics, recently announced they have successfully dosed the first subject in a Phase I clinical trial of TKM-HBV – a therapeutic drug ... Read more